Shopping Cart
Remove All
Your shopping cart is currently empty
NLRP3/URAT1-IN-1
Catalog No. T213170 Copy Product Info
🥰Excellent
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. It suppresses IL-1β release in mouse bone marrow-derived macrophages (BMDMs) stimulated by LPS and ATP, with an IC50 of 2.61 μM. Additionally, NLRP3/URAT1-IN-1 decreases serum uric acid (SUA) levels and alleviates liver/kidney injury in mice with acute hyperuricemia (HUA). This compound is relevant for research on gout and hyperuricemia.
NLRP3/URAT1-IN-1
Copy Product Info🥰Excellent
Catalog No. T213170
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. It suppresses IL-1β release in mouse bone marrow-derived macrophages (BMDMs) stimulated by LPS and ATP, with an IC50 of 2.61 μM. Additionally, NLRP3/URAT1-IN-1 decreases serum uric acid (SUA) levels and alleviates liver/kidney injury in mice with acute hyperuricemia (HUA). This compound is relevant for research on gout and hyperuricemia.
NLRP3/URAT1-IN-1
Cas No. 2994637-53-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. It suppresses IL-1β release in mouse bone marrow-derived macrophages (BMDMs) stimulated by LPS and ATP, with an IC50 of 2.61 μM. Additionally, NLRP3/URAT1-IN-1 decreases serum uric acid (SUA) levels and alleviates liver/kidney injury in mice with acute hyperuricemia (HUA). This compound is relevant for research on gout and hyperuricemia. |
| Targets&IC50 | IL-1β:2.61 μM |
| In vitro | NLRP3/URAT1-IN-1 (Compound 32) demonstrates potent inhibitory activity against URAT1 in HEK293 cells overexpressing URAT1 with an IC50 value of 3.81 μM. It also inhibits OAT4 in HEK293-OAT4 cells using 6-carboxyfluorescein (6-CFL) as a substrate with an IC50 of 6.08 μM. In HEK293-GLUT9 cells overexpressing GLUT9, NLRP3/URAT1-IN-1 shows inhibitory effects with an IC50 of 11.02 μM, determined by whole-cell patch-clamp recording. Furthermore, at a concentration of 3 μM for 45 minutes, it reduces IL-1β release in LPS and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs) with an IC50 of 2.61 μM, without affecting the production of TNF-α and IL-6. In human liver microsomes, it exhibits moderate inhibition of CYP2C9 (IC50 = 2.77 μM) and CYP2C19 (IC50 = 2.03 μM). |
| In vivo | NLRP3/URAT1-IN-1 (Compound 32) at a dose of 2 mg/kg, administered orally as a single dose, significantly reduces serum uric acid (SUA) levels in mice with acute hyperuricemia (HUA) induced by hypoxanthine and potassium oxonate. Moreover, a daily oral dose of 2 mg/kg for 3 days significantly alleviates ankle swelling in rats with acute gouty arthritis induced by intra-articular injection of MSU crystals. |
| Molecular Weight | 525.44 |
| Formula | C24H17BrN2O3S2 |
| Cas No. | 2994637-53-3 |
| Smiles | O=C(NS(=O)(=O)C=1SC=CC1)C2=CC=3C=CC=CC3N2CC4=CC=C(Br)C=5C=CC=CC54 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy NLRP3/URAT1-IN-1 | purchase NLRP3/URAT1-IN-1 | NLRP3/URAT1-IN-1 cost | order NLRP3/URAT1-IN-1 | NLRP3/URAT1-IN-1 in vivo | NLRP3/URAT1-IN-1 in vitro | NLRP3/URAT1-IN-1 formula | NLRP3/URAT1-IN-1 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.